The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1707
July 22, 2024
View Complete Issue         Table of Contents 2019 
Iloprost (Aurlumyn) for Frostbite
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Iloprost (Aurlumyn) for Frostbite
July 22, 2024 (Issue: 1707)
The FDA has approved Aurlumyn (Eicos Sciences), an IV formulation of the prostacyclin analog iloprost, to reduce the risk of digit amputation in adults with severe frostbite. Iloprost is the first drug to be approved by the FDA for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Iloprost (Aurlumyn) for Frostbite
Article code: 1707b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.